Therapy Detail

Therapy Name MK-8745
Therapy Description

MK-8745 is selective Aurora A kinase inhibitor, which induces cell cycle arrest (PMID: 21879811).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MK-8745 Aurka Inhibitors 23 MK-8745 is selective Aurora A kinase inhibitor, which induces cell cycle arrest (PMID: 21879811).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 wild-type colorectal cancer predicted - sensitive MK-8745 Preclinical - Cell culture Actionable In a preclinical study, MK-8745 treatment resulted in apoptosis in Tp53 wild-type colorectal cancer cells in culture (PMID: 22293494). 22293494
Clinical Trial Phase Therapies Title Recruitment Status